Back to Search
Start Over
Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021
- Source :
- Medisur, Vol 22, Iss 1, Pp 120-126 (2024)
- Publication Year :
- 2024
- Publisher :
- Centro Provincial de Información de Ciencias Médicas. Cienfuegos, 2024.
-
Abstract
- Foundation: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country. Objective: to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients. Methods: a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records. Results: morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%). Conclusions: resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases.
Details
- Language :
- Spanish; Castilian
- ISSN :
- 1727897X
- Volume :
- 22
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Medisur
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.f93995219a6041a2a9193939f3c95718
- Document Type :
- article